NervGen Q2 2026 loss reflects continued spending on NVG-291, NVG-300 development, company says
NGEN•NervGen says Q2 loss was driven by ongoing development spending
NervGen’s commentary for the three and six months ended June 30, 2026 centered on continued spending tied to development of NVG-291.
Management highlighted preparations to initiate a Phase 3 trial in chronic tetraplegia as the key operational driver.
Development pace remained influenced by an FDA partial clinical hold on NVG-291 for spinal cord injury.
The company framed near-term performance around funding needs, cash use, and the timing of clinical milestones.
